Nephrocare Health Services Ltd will auction 8.9% of its equity, amounting to ₹650 crore, in a block deal scheduled for Thursday. The base offer covers 5.5% of the company for ₹400 crore, with an upsizing option of 3.4% for ₹250 crore.
The offer price is ₹705 per share, a 5% discount to the last closing price of ₹741.85. The discount aligns with the 0.99% fall recorded on the BSE after the announcement.
Investors backing the deal include Investcorp Private Equity Fund II, Healthcare Parent Limited, Investcorp India Private Equity Opportunity Limited, Edoras Investment Holdings Pte Ltd, Quadria Capital India Fund III, Bessemer Venture Partners Trust, Vikram Vuppala, Viraaj Family Trust and Manvi Family Trust.
Nephrocare’s CFO Prashant Goenka reiterated a 15‑20% revenue‑growth target for the next three to four years, driven by expansion across India and overseas markets. International revenue now accounts for 42% of total, up from 32% last year, and the company added 52 new centres in India and completed 11 acquisitions in the Philippines in FY25.
The block deal comes as shares closed lower 0.99% at ₹741.85 on the BSE, reflecting investor caution amid the discount. Nephrocare has not yet set revised guidance, but analysts expect the transaction to reduce debt burden and support the company’s growth plan, according to the company’s filing.